NCT05682326View on ClinicalTrials.gov

Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)

PHASE3CompletedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

March 17, 2025

Study Completion Date

March 17, 2025

Conditions

Anaemia

Interventions

DRUG

Daprodustat

Daprodustat will be administered up to Week 52.

Trial Locations (4)

50612

GSK Investigational Site, Yangsan

466-8650

GSK Investigational Site, Aichi

330-8777

GSK Investigational Site, Saitama

162-8666

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT05682326 - Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P) | Biotech Hunter | Biotech Hunter